A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia

JAMA Psychiatry

Volumn 74, Issue 12, 2017, Pages 1206-1213

  Jauhar, Sameer ^a,b   Nour, Matthew M ^a,c   Veronese, Mattia ^a   Rogdaki, Maria ^c   Bonoldi, Ilaria ^a,b   Azis, Matilda ^a   Turkheimer, Federico ^a   McGuire, Philip ^a,b   Young, Allan H ^a   Howes, Oliver D ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; DOPAMINE; DOPA; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORINE; FLUORINE-18;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DOPAMINE METABOLISM; ENGLAND; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; SCHIZOPHRENIA; YOUNG MANIA RATING SCALE; BIOSYNTHESIS; CASE CONTROL STUDY; COMPLICATION; METABOLISM; PROCEDURES; PSYCHOLOGICAL RATING SCALE; REPRODUCIBILITY;

ADULT; BIPOLAR DISORDER; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE AGENTS; ENGLAND; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 85037862790     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.2943     Document Type: Article

References (72)

1. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64 (1):19-28.
2. Insel T, Cuthbert B, GarveyM, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748-751.
3. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry. 1991;148(11):1474-1486.
4. Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81(1):9-20.
5. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia, version III: the final common pathway. Schizophr Bull. 2009;35(3):549-562.
6. Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull. 2010;36(3):472-485.
7. Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17(8):524-532.
8. Heinz A, Schlagenhauf F, Beck A, Wackerhagen C. Dimensional psychiatry: mental disorders as dysfunctions of basic learning mechanisms. J Neural Transm (Vienna). 2016;123 (8):809-821.
9. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999;13(4): 358-371.
10. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A. 1994;91(24):11651-11654.
11. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776-786.
12. Egerton A, Chaddock CA, Winton-Brown TT, et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013;74(2):106-112.
13. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13-20.
14. Howes OD, Bose SK, Turkheimer F, et al. Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study. Am J Psychiatry. 2011;168(12):1311-1317.
15. Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study. Mol Psychiatry. 2011;16(9):885-886.
16. Bloemen OJ, de Koning MB, Gleich T, et al. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. Eur Neuropsychopharmacol. 2013;23(2): 126-132.
17. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1): 21-32.
18. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64 (5):543-552.
19. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. Vol 1. New York, NY: Oxford University Press; 2007.
20. Nusslock R, Young CB, Damme KSF. Elevated reward-related neural activation as a unique biological marker of bipolar disorder: Assessment and treatment implications. Behav Res Ther. 2014; 62:74-87.
21. Abler B, Greenhouse I, Ongur D, Walter H, Heckers S. Abnormal reward system activation in mania. Neuropsychopharmacology. 2008;33(9): 2217-2227.
22. Pearlson GD, Wong DF, Tune LE, et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry. 1995;52(6):471-477.
23. Ko GN, Leckman JF, Heninger GR. Induction of rapid mood cycling during L-dopa treatment in a bipolar patient. Am J Psychiatry. 1981;138(12): 1624-1625.
24. Jacobs D, Silverstone T. Dextroamphetamineinduced arousal in human subjects as a model for mania. Psychol Med. 1986;16(2):323-329.
25. McTavish SF, McPherson MH, Harmer CJ, et al. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry. 2001;179:356-360.
26. Kemperman CJ, Zwanikken GJ. Psychiatric side effects of bromocriptine therapy for postpartum galactorrhoea. J R Soc Med. 1987;80(6):387-388.
27. Scarna A, Gijsman HJ, McTavish SF, Harmer CJ, Cowen PJ, Goodwin GM. Effects of a branched-chain amino acid drink in mania. Br J Psychiatry. 2003; 182:210-213.
28. van Enkhuizen J, GeyerMA, Halberstadt AL, Zhuang X, Young JW. Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord. 2014;155(1):247-254.
29. Harsch HH, Miller M, Young LD. Induction of mania by L-dopa in a nonbipolar patient. J Clin Psychopharmacol. 1985;5(6):338-339.
30. Fisher G, Pelonero AL, Ferguson C. Mania precipitated by prednisone and bromocriptine. Gen Hosp Psychiatry. 1991;13(5):345-346.
31. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull. 2008;41(4):37-47.
32. Sidor MM, Spencer SM, Dzirasa K, et al. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry. 2015;20(11): 1406-1419.
33. NolenWA. Dopamine and mania: the effects of trans-and cis-clopenthixol in a double-blind pilot study. J Affect Disord. 1983;5(2):91-96.
34. Yatham LN, Liddle PF, Shiah IS, et al. PET study of [18F]6-fluoro-L-dopa uptake in neuroleptic-and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry. 2002;159(5):768-774.
35. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, DC: American Psychiatric Press Inc; 1997.
36. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
38. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435.
39. Leucht S, Winter-van Rossum I, Heres S, et al. The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015;41 (3):549-558.
40. Bloomfield MA, Pepper F, Egerton A, et al. Dopamine function in cigarette smokers: An [18F]-DOPA PET study. Neuropsychopharmacology. 2014;39(10):2397-2404.
41. Cumming P, Leger GC, Kuwabara H, Gjedde A. Pharmacokinetics of plasma 6-[18F]fluoro-L-3, 4-dihydroxyphenylalanine ([18F]FDOPA) in humans. J Cereb Blood Flow Metab. 1993;13(4):668-675.
42. Jauhar S, Veronese M, Rogdaki M, et al. Regulation of dopaminergic function: An [18F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry. 2017;7(2):e1027.
43. Kegeles LS, Abi-Dargham A, FrankleWG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67(3):231-239.
44. Howes OD, Williams M, Ibrahim K, et al. Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study. Brain. 2013;136(pt 11): 3242-3251.
45. SPM. Statistical parametric mapping. http://www.fil.ion.ucl.ac.uk/spm/. Accessed October 5, 2016.
46. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage. 2010;50(2):524-531.
47. Gousias IS, Rueckert D, Heckemann RA, et al. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage. 2008;40(2):672-684.
48. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography, part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23(3):285-300.
49. Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: A review of clinical findings and modeling approaches. Neuroscientist. 2009;15(6):635-650.
50. Microsoft Excel for Mac [computer program]. Version 15. Redmond, Washington: Microsoft Office Home & Student; 2016 for PC.
51. SPSS [computer program]. Version 23. Chicago, IL: SPSS Inc; 2009.
52. Ashok AH, Marques TR, Jauhar S, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22(5):666-679.
53. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord. 2009; 11(8):787-806.
54. Hietala J, Syvalahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res. 1999;35(1):41-50.
55. Bose SK, Turkheimer FE, Howes OD, et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res. 2008;106(2-3):148-155.
56. Lindstrom LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β-11C) DOPA and PET. Biol Psychiatry. 1999;46(5):681-688.
57. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5(3):267-271.
58. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. 6-18F-DOPA PET study in patients with schizophrenia. Psychiatry Res. 2000;100(1):1-11.
59. Salvatore P, Baldessarini RJ, Tohen M, et al. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009;70(4):458-466.
60. Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Grasby PM. Correction of head movement on PET studies: comparison of methods. J Nucl Med. 2006;47(12):1936-1944.
61. Bunney BS, Grace AA. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci. 1978;23 (16):1715-1727.
62. Danielsen EH, Smith D, Hermansen F, Gjedde A, Cumming P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse. 2001;41(2):172-175.
63. Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997;20(1):31-37.
64. Grunder G, Vernaleken I, Muller MJ, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology. 2003; 28(4):787-794.
65. Cumming P. Imaging Dopamine. New York, NY: Cambridge University Press; 2009.
66. Sossi V, Doudet DJ, Holden JE. A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab. 2001;21(4):469-476.
67. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5(4):584-590.
68. Hartvig P, Agren H, Reibring L, et al. Brain kinetics of L-[β-11C]DOPA in humans studied by positron emission tomography. J Neural Transm Gen Sect. 1991;86(1):25-41.
69. Anand A, Verhoeff P, Seneca N, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000;157(7):1108-1114.
70. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306-1315.
71. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013; 382(9896):951-962.
72. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75(5):e11-e13.